Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DE-105 in Persistent Corneal Epithelial Defect
NCT00988494Phase 2Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Sep 2009
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of DE-105 in persistent corneal epithelial defect (PED) (3 arms), sponsored by Santen Pharmaceutical. Primary endpoint: Restoration of corneal epithelial defect. Started Sep 2009; status: completed.
02
Drugs
DE-105
03
Conditions
persistent corneal epithelial defect (PED)
Beyond the preview
Go deeper on NCT00988494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00988494.